...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution
【24h】

Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution

机译:造血细胞移植前,期间和后的策略改善T细胞免疫重建

获取原文
获取原文并翻译 | 示例

摘要

T-cell immune reconstitution (IR) after allogeneic hematopoietic cell transplantation (allo-HCT) is highly variable between patients and may take several months to even years. Patients with delayed or unbalanced T-cell IR have a higher probability of developing transplantation-related morbidity, mortality, and relapse of disease. Hence, there is a need for strategies to better predict and improve IR to reduce these limitations of allo-HCT. In this review, we provide an update of current and in-near-future clinically relevant strategies before, during, and after transplantation to achieve successful T-cell IR. Potent strategies are choosing the right HCT source (eg, donor-recipient matching, cell dose, graft manipulation), individualized conditioning and serotherapy (eg, antithymocyte globulin), nutritional status, exercise, home care, modulation of microbiota, enhancing homeostatic peripheral expansion, promoting thymopoiesis, and the use of adjuvant-targeted cellular immunotherapies. Strategies to prevent graft-versus-host disease are important as well because this complication and the subsequent need for immunosuppression affects T-cell IR and function. These options aim for personalized precision transplantation, where allo-HCT therapy is designed to boost a well balanced T-cell IR and limit complications in individual patients, resulting in overall lower morbidity and higher survival chances.
机译:在同种异体造血细胞移植(Allo-Hct)之间的T细胞免疫重建(IR)在患者之间具有高度变化,可能需要几个月甚至甚至几年。 T细胞IR延迟或不平衡患者具有发育移植相关的发病率,死亡率和疾病复发的概率较高。因此,需要更好地预测和改善IR来减少allo-hct的这些限制的策略。在本次审查中,我们在移植之前,期间和后,在移植之前,期间和结束后的临床相关策略更新,以实现成功的T细胞IR。有效的策略是选择右旋源(例如,供体 - 受体匹配,细胞剂量,接枝处理),个体化调理和疗程(例如,抗静电细胞球蛋白),营养状况,运动,家庭护理,微生物瘤的调节,增强了稳态外周枢痛,促进胸腺孢子,以及使用佐剂靶向细胞免疫疗法。预防移植物与宿主病的策略也很重要,因为这种并发症和随后的免疫抑制需要影响T细胞IR和功能。这些选项旨在进行个性化精密移植,其中Allo-HCT疗法旨在提高良好的平衡T细胞IR并限制个体患者的并发症,导致总体发病率和更高的存活机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号